SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how effective Sunitinib works in treating acral
lentiginous and mucosal melanoma which has spread beyond the local region. Suninitib is a
protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work
by blocking signals on certain cancer cells which allow the malignant cells to multiply and
spread due to a change in the genetic make up of the cancer cell.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Massachusetts General Hospital Pfizer